Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: Long-Term analysis

Kidney and Blood Pressure Research

Volumn 32, Issue 4, 2009, Pages 268-275

  Ozturk, Savas ^a,c   Sar, Fuat ^b   Bengi Bozkurt, Olcay ^b   Kazancioglu, Rumeyza ^a  

^a Department of Nephrology ^*  (Turkey)

^b HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c Haseki Egitim Ve Arsatirma Hastanesi Ic Hastaliklari   (Turkey)

Author keywords

ACE inhibitor; Angiotensin II receptor blocker; Chronic kidney disease; Diabetic nephropathy; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DIALYSIS; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; SODIUM BLOOD LEVEL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LONG-TERM CARE; MALE; MIDDLE AGED; PROTEINURIA; TREATMENT OUTCOME;

EID: 70349258114     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000239765     Document Type: Article

References (29)

1. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: 477-486.
2. Anderson S: Role of local and systemic angiotensin in diabetic renal disease. Kidney Int Suppl 1997; 63: 107-110.
3. Rossing P, Hommel E, Smidt UM, Parving HH: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 1994; 45: 145-149.
4. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA 2003; 290: 2159-2167.
5. Adler AI, Stratton IM, Neil HA, et al: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419.
6. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR: Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324: 78-84.
7. Anderson S, Rennke HG, Garcia DL, Brenner BM: Short- and long-term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36: 526-536.
8. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581.
9. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: 150-155.
10. Chan JC, Ko GT, Leung DH, et al: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600.
11. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097.
12. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
13. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869. (Pubitemid 34940825)
14. Ahmad J, Siddiqui MA, Ahmad H: Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20: 1576-1581.
15. Lacourcière Y, Bélanger A, Godin C, et al: Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetic patients with early nephropathy. Kidney Int 2000; 58: 762-769.
16. Barnett AH, Bain SC, Bouter P, et al: Angiotensin receptor blockade versus convertingenzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961.
17. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
18. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762.
19. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44: 1303-1309.
20. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: 1-266.
21. Chobanian AV, Bakris GL, Black HR, et al: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
22. EUCLID Study Group: Randomised placebo- controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
23. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 128: 982-988.
24. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
25. Coronel F, Cigarrán S, García-Mena M, Herrero JA, Calvo N, Pérez-Flores I: Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI (in Spanish). Nefrologia 2008; 28: 56-60.
26. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET Investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372: 547-553.
27. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-771.
28. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A: Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992; 42: 46-55.
29. Yoneda T, Takeda Y, Usukura M, et al: Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 2007; 20: 1329-1333.